Information Provided By:
Fly News Breaks for October 21, 2019
AMED
Oct 21, 2019 | 16:15 EDT
Stephens analyst Scott Fidel resumed coverage of Amedisys with an Equal Weight rating and $145 price target. The company's core home health business should benefit from strong long-term secular tailwinds, though in the near-term the implementation of the Patient-Driven Groupings Model, or PDGM, creates a tough reimbursement environment for 2020, said Fidel.
News For AMED From the Last 2 Days
There are no results for your query AMED